Pharmacokinetic-Pharmacodynamic (Dipeptidyl Peptidase-4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those with Renal Impairment, for the Once-Weekly Administered Omarigliptin.

Clicks: 272
ID: 19455
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #13 of 44 articles by views in British journal of clinical pharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To characterize the population pharmacokinetics (PK) and pharmacodynamics (PD) of the once-weekly (q.w.) dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin in healthy subjects and patients with type 2 diabetes mellitus (T2DM), and use these models to support the dosing recommendation for patient labeling including patients with renal impairment.PK and PD were assessed from a total of 9827 omarigliptin concentrations collected from 1387 healthy subjects and patients participating in Phase 1, 2, and 3 studies examining single- or multiple-dose weekly administration of omarigliptin at doses ranging from 0.25 mg to 400 mg. Population PK and PD analyses were performed using non-linear mixed effect modeling.A semi-mechanistic two-compartment model with linear unbound clearance and concentration-dependent binding of omarigliptin to the DPP-4 enzyme in both the central and peripheral compartments adequately described omarigliptin PK. Key covariates on omarigliptin PK included reduced unbound clearance with renal impairment. A direct effect sigmoid E model adequately described the relationship between omarigliptin plasma concentrations and DPP-4 inhibition. These models supported the current Japan label instructions that the approved omarigliptin 25 mg q.w. dose be halved in patients with severe renal impairment and in those with end-stage renal disease (ESRD). Also, if patients missed a dose, the next dose of omarigliptin should be taken as soon as remembered up to and including the day before the next scheduled dose. No other clinically important covariates were identified.The models in the present analysis adequately described PK and PD characteristics of omarigliptin and supported the dosing and administration section of the omarigliptin label.
Reference Key
jain2019pharmacokineticpharmacodynamicbritish Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jain, Lokesh;Chain, Anne S Y;Tatosian, Daniel A;Hing, Jeremy;Passarell, Julie A;Kauh, Eunkyung A;Lai, Eseng;
Journal British journal of clinical pharmacology
Year 2019
DOI
10.1111/bcp.14103
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.